@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAZ0UjlXaVw1knTmShJGQe3xlMfhzq-BkzRbxMwm66YF0> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAZ0UjlXaVw1knTmShJGQe3xlMfhzq-BkzRbxMwm66YF0#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix mgi: <http://www.informatics.jax.org/marker/MGI:> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: mgi:97275;
    a Protein: .
  
  sub:_2 hasAgent: sub:_3;
    a go:0042789 .
  
  sub:_3 geneProductOf: mgi:99458;
    a Protein: .
  
  sub:_4 occursIn: species:10090;
    rdf:object sub:_2;
    rdf:predicate belv:increases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "p(MGI:Myod1) -> tscript(p(MGI:Mef2c))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_6;
    pav:version "1.4" .
  
  sub:_5 prov:value "Because these residues are required for enhanced MEF2C activity in monocytic cells, we tested whether MyoD activation of Gal4-MEF2C required the same amino acids. The combined mutation of both Thr293 and Thr300 to alanine (T293;300A) did not affect the basal activity of Gal4-MEF2C (Figure 3b, compare columns 3 and 5), but did enhance the activity of Gal4-MEF2C when MyoD+E12 were co-expressed (Figure 3b, compare columns 4 and 6). In contrast, mutation of Ser387 to alanine (S387A) decreased the basal activity of Gal4-MEF2C and completely eliminated its activation by co-transfected MyoD+E12 (Figure 3b, columns 7,8). Importantly, activation of the p38 kinase pathway did stimulate the function of the S387A Gal4-MEF2C mutant (data not shown; see also [25,27]), indicating that this mutation does not simply inactivate the protein. Therefore, MyoD activation of the MEF2C TAD requires Ser387, but neither Thr293 nor Thr300, of MEF2C.";
    prov:wasQuotedFrom pubmed:10322110 .
  
  sub:_6 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:10322110;
    prov:wasDerivedFrom beldoc:, sub:_5 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:29:47.083+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}